Table 5.
Significantly different protein expression across age groups and differential regulation of the expression subjected to mean transformation values (Z-scores)
| Accession Number | Description | Transformed Intensity Value* † | p | Z score* | ||||||
| Group 30 | Group 40 | Group 50 | Group≥60 | Group 30 | Group 40 | Group 50 | Group≥60 | |||
| P0CG04 | Immunoglobulin lambda-1 chain C regions (IGLC1) | 2.93 | 1.29 | –9.22a,b | –3.95a,b | 0.01 | 0.98 | 0.67 | –1.32 | –0.32 |
| P00739 | Haptoglobin-related protein (HPTR) | 1.55 | 0.90 | –1.91a,b | –0.99a | 0.04 | 1.03 | 0.63 | –1.12 | –0.54 |
| P01714 | Immunoglobulin lambda variable 3–19 (IGLV3–19) | –3.11 | –2.78 | –4.76a,b | –4.50b | 0.04 | 0.68 | 1.01 | –0.98 | –0.71 |
| P02753 | Retinol-binding protein 4 (RBP4) | 3.06 | 2.19 | –0.87 | –6.07a,b | 0.03 | 0.85 | 0.64 | –0.11 | –1.38 |
| P04070 | Vitamin K-dependent protein C (PROC) | –4.45 | –5.80 | –7.71a | –7.48a | 0.04 | 1.24 | 0.36 | –0.88 | –0.73 |
| P04180 | Phosphatidylcholine-sterol acyltransferase (LCAT) | –3.19 | –2.50 | –6.44a,b | –5.58b | 0.03 | 0.66 | 1.03 | –1.08 | –0.62 |
| P04433 | Immunoglobulin kappa variable 3–11 (IGKV3–11) | –1.03 | –2.66 | –6.43a,b | –7.49a,b | 0.01 | 1.16 | 0.60 | –0.69 | –1.06 |
| P05154 | Plasma serine protease inhibitor (SERPINA5) | –2.73 | –3.84 | –7.55a,b | –6.15a | 0.04 | 1.07 | 0.56 | –1.13 | –0.49 |
| P06727 | Apolipoprotein A-IV (APOA4) | 4.86 | 4.28 | –1.30a,b,d | 5.59 | 0.00 | 0.51 | 0.31 | –1.57 | 0.75 |
| P07360 | Complement component C8 gamma chain (C8G) | –0.72 | –1.34 | –2.39a,b | –1.49 | 0.04 | 1.10 | 0.21 | –1.30 | –0.01 |
| P08519 | Apolipoprotein(a) (LPA) | –3.35 | –3.11 | –5.07a,b | –5.26a,b | 0.02 | 0.77 | 0.99 | –0.8 | –0.97 |
| P15169 | Carboxypeptidase N catalytic chain (CPN1) | –0.37 | –1.78 | –6.80a,b | –4.94a,b | 0.01 | 1.12 | 0.61 | –1.20 | –0.53 |
| P18206 | Vinculin (VCL) | –4.25 | –3.39 | –7.09a,b | –5.741a,b,c | 0.00 | 0.57 | 1.12 | –1.28 | –0.41 |
| P18428 | Lipopolysaccharide-binding protein (LBP) | –3.65 | –1.99 | –6.32b | –5.68b | 0.03 | 0.39 | 1.23 | –0.97 | –0.64 |
| P27169 | Serum paraoxonase/arylesterase 1 (PON1) | 4.23 | 4.00 | –0.01a,b | 2.06 | 0.03 | 0.85 | 0.73 | –1.32 | –0.26 |
| P32119 | Peroxiredoxin–2 (PRDX2) | –2.75 | –2.56 | –7.09a,b | –5.68 | 0.04 | 0.78 | 0.87 | –1.14 | –0.52 |
| P35542 | Serum amyloid A–4 protein (SAA4) | 0.93 | 2.28 | –7.34a,b | –6.37a,b | 0.01 | 0.76 | 1.05 | –1.01 | –0.80 |
| P35858 | Insulin-like growth factor-binding protein complex acid labile subunit (IGFALS) | –1.06 | –0.14 | –2.39b | –2.52b | 0.04 | 0.41 | 1.21 | –0.75 | –0.86 |
| Q16610 | Extracellular matrix protein 1 (ECM1) | –3.90 | –3.46 | –5.71a,b | –7.31a,b | 0.01 | 0.71 | 0.96 | –0.36 | –1.31 |
| Q92954 | Proteoglycan 4 (PRG4) | –3.77 | –2.73 | –7.90a,b | –5.54a,b,c | 0.00 | 0.57 | 1.05 | –1.36 | –0.26 |
| Q961Y4 | Carboxypeptidase B2 (CPB2) | –3.52 | –3.42 | –5.71a,b | –7.80a,b | 0.01 | 0.80 | 0.85 | –0.30 | –1.34 |
| Q96KN2 | Beta-Ala-His dipeptidase (CNDP1) | –4.53 | –4.02 | –6.21a,b | –5.50b | 0.01 | 0.56 | 1.11 | –1.20 | –0.46 |
| Q9UGM5 | Fetuin-B (FETUB) | –0.54 | –0.84 | –6.68a,b | –4.47 | 0.03 | 0.88 | 0.78 | –1.20 | –0.45 |
| Q9UK55 | Protein Z-dependent protease inhibitor (SERPINA10) | –3.88 | –2.57 | –6.99b | –7.16b | 0.04 | 0.55 | 1.12 | –0.80 | –0.87 |
*Displayed value was based on the reading of sample replicates. †Demonstrated intensity value was subjected to log2 transformation and width adjustment for data normalization. @Post hoc analysis was conducted to determine disparity among the groups. Reported p value was based on two-tailed test. asignificant different (p < 0.05) compared to Group 30. significant different (p < 0.05) compared to Group 40. csignificant different (p < 0.05) compared to Group 50.